In conclusion, although gabapentinoids and duloxetine are still widely used as first-line treatments for DPN, the adverse effects associated with their mechanisms of action have become key factors limiting their long-term clinical application
These materials can be incorporated with peptides cleaved by specific enzymes, such as trypsin and cathepsin, leading to selective drug or imaging agent activation/release
Disclosures: Mengya Zang: Nothing to Disclose, Peilin Zhu: Nothing to Disclose, Qingxian Cai: Nothing to Disclose, Haojie Liao: Nothing to Disclose, Dayong Zheng: Nothing to Disclose, Feng Shi: Nothing to Disclose, Hualang Cai: Nothing to Disclose, Xuan Wu: Nothing to Disclose, QI Li: Nothing to Disclose, Huajin Pang: Nothing to Disclose 1809 THE HIPPO PATHWAY EFFECTOR TAZ IS REQUIRED FOR NOTCH-DRIVEN CHOLANGIOCARCINOGENESIS VIA METTL3-MEDIATED M6A MODIFICATION Wenbo Ma 1 Jinqiang Zhang 2 Weina Chen 1 Nianli Liu 2 Tong Wu 3 , 1 Tulane University School of Medicine, 2 Tulane University, 3 Tulane Medical Center Background: Notch and TAZ are implicated in cholangiocarcinogenesis, but whether and how these oncogenic molecules interact remain unknown
Biomarker guidance (Prx redox state, GSH/GSSG, LIP assays, cysteine-oxidation proteomics, compartment-targeted reporters) helps titrate dose, route and timing, minimizing off-target effects and avoiding the common pitfall of trading one pathology for another by over-suppressing beneficial stress responses (Murphy et al
